|Trade names||Harmogen, Improvera, Ogen, Ortho-Est, Sulestrex, others|
|Other names||Piperazine estrone sulfate; Estrone sulfate piperazine salt; Pipestrone|
|Main uses||Menopause, ovarian failure|
|Side effects||Headache, breast pain, irregular vaginal bleeding, abdominal cramps, nausea|
|Chemical and physical data|
|Molar mass||436.57 g·mol−1|
|3D model (JSmol)|
Estropipate, sold under the brand name Ogen among others, is a medication used to treat the symptoms of menopause and ovarian failure. It was previously also used to prevent postmenopausal osteoporosis. It is taken by mouth.
Common side effects include headache, breast pain, irregular vaginal bleeding, abdominal cramps, and nausea. Other side effects may include high blood pressure, liver problems, high sugar, swelling, hair loss, and vaginal yeast infections. Rarely blood clots or gallbladder disease may occur. It is an estrogen, specifically a salt of estrone sulfate and piperazine, which is transformed into estrone and estradiol in the body.
Estropipate was first made commercially in the United States in 1950. In the United States 100 tablets of 0.75 mg used to cost about 50 USD. Production; however, has been discontinued in the United States as of 2021.
Estropipate is used to:
- Alleviate symptoms of menopause as menopausal hormone therapy
- Treat some types of infertility
- Treat some conditions leading to underdevelopment of female sexual characteristics
- Treat vaginal atrophy
- Treat some types of breast cancer (particularly in men and postmenopausal women)
- Treat prostate cancer
- Prevent osteoporosis
|Oral||Estradiol||0.5–1 mg/day||1–2 mg/day||2–4 mg/day|
|Estradiol valerate||0.5–1 mg/day||1–2 mg/day||2–4 mg/day|
|Estradiol acetate||0.45–0.9 mg/day||0.9–1.8 mg/day||1.8–3.6 mg/day|
|Conjugated estrogens||0.3–0.45 mg/day||0.625 mg/day||0.9–1.25 mg/day|
|Esterified estrogens||0.3–0.45 mg/day||0.625 mg/day||0.9–1.25 mg/day|
|Estropipate||0.75 mg/day||1.5 mg/day||3 mg/day|
|Estriol||1–2 mg/day||2–4 mg/day||4–8 mg/day|
|Ethinylestradiola||2.5 μg/day||5–15 μg/day||–|
|Nasal spray||Estradiol||150 μg/day||300 μg/day||600 μg/day|
|Transdermal patch||Estradiol||25 μg/dayb||50 μg/dayb||100 μg/dayb|
|Transdermal gel||Estradiol||0.5 mg/day||1–1.5 mg/day||2–3 mg/day|
|Estriol||30 μg/day||0.5 mg 2x/week||0.5 mg/day|
|IM or SC injection||Estradiol valerate||–||–||4 mg 1x/4 weeks|
|Estradiol cypionate||1 mg 1x/3–4 weeks||3 mg 1x/3–4 weeks||5 mg 1x/3–4 weeks|
|Estradiol benzoate||0.5 mg 1x/week||1 mg 1x/week||1.5 mg 1x/week|
|SC implant||Estradiol||25 mg 1x/6 months||50 mg 1x/6 months||100 mg 1x/6 months|
|Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: See template.|
Society and culture
Estropipate appears to remain available only in the United States. In the past, estropipate has also been marketed in Canada, the United Kingdom, Ireland, Switzerland, Australia, South Africa, Mexico, and Indonesia. There is no manufacturer selling the medication in Canada as of 2021.
- "DailyMed - ESTROPIPATE tablet". dailymed.nlm.nih.gov. Archived from the original on 11 January 2022. Retrieved 17 December 2021.
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 900–. ISBN 978-1-4757-2085-3. Archived from the original on 27 June 2021. Retrieved 19 October 2020.
- Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 114–. ISBN 978-94-011-4439-1.
- Report on Carcinogens: Carcinogen Profiles. Department of Health and Human Services, Public Health Service, National Toxicology Program. 2000. p. RA1-PA26. Archived from the original on 2022-01-11. Retrieved 2021-12-17.
- "Estropipate Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 17 December 2021.
- "Estropipate Prices and Estropipate Coupons - GoodRx". GoodRx. Retrieved 17 December 2021.
- "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 22 March 2021. Retrieved 19 December 2021.
- "Ogen, estropipate tablets, USP" (PDF). Pharmacia & Upjohn Co. U.S. Food and Drug Administration. December 2004. Archived (PDF) from the original on 2021-04-04. Retrieved 2020-10-19.
- DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML (23 January 2017). Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition. McGraw-Hill Education. p. 1295. ISBN 978-1-259-58749-8. Archived from the original on 26 March 2019. Retrieved 19 October 2020.
- Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2101. ISBN 978-0-85369-840-1. Archived from the original on 2021-11-01. Retrieved 2020-10-19.
- Budoff PW (1 August 1983). No more hot flashes, and other good news. Putnam. p. 28. ISBN 978-0-399-12793-9.
- P & T. CORE Medical Journals. July 1993. Archived from the original on 2021-11-02. Retrieved 2020-10-19.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 408–. ISBN 978-3-88763-075-1. Archived from the original on 2021-11-01. Retrieved 2020-10-19.
- "Estropipate". Drugs.com. Archived from the original on 2019-08-24. Retrieved 2020-10-19.
- "Estropipate". www.dpic.org. Archived from the original on 16 April 2021. Retrieved 17 December 2021.